Skip to content
value.today

Accuray Incorporated: financial analysis

Ratios worked out from 10 fiscal years of Accuray Incorporated's statements, compared with 102 companies in Medical Devices.

Operating margin, 2026
-6.6%
Medical Devices: -8.2%
Return on equity, 2026
-80.1%
Medical Devices: -16.8%
Revenue growth, 3 years a year, 2026
-3.5%
Medical Devices: 10.8%
Debt to equity, 2026
3.55×
Medical Devices: 0.64×

Accuray Incorporated scorecard#

Passes 4 of the 20 checks that could be worked out: strongest in valuation (2 of 5), weakest in growth (0 of 5). Fiscal year 2026; market cap of Oct 30, 2026.

  • Valuation2 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median0.4×Price to book 0.4× against Medical Devices's median of 2.5×.
    • ✓Price to sales below its peers' median0.0×Price to sales 0.0× against Medical Devices's median of 2.4×.
    • ✗Free cash flow yield above 5%-76.3%Free cash flow is -76.3% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 5
    • ✗Revenue grew in the newest year-12.3%Revenue down 12.3% in fiscal 2026.
    • ✗Revenue up more than 5% a year over three years-3.5%-3.5% a year over the three years to fiscal 2026.
    • ✗Faster growth over three years than its peers' median-3.5%-3.5% a year against Medical Devices's median of 10.8% (73 companies).
    • –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
    • ✗Net income higher than five years earlier-$49 M-$49 M in fiscal 2026 against -$6 M in 2021.
    • ✗Revenue rose in at least four of the last five years3 of 5Revenue rose in 3 of the five years to fiscal 2026.
  • Profitability1 of 5
    • ✗Profitable in the newest year-$49 MNet income -$49 M in fiscal 2026.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2026.
    • ✓Operating margin above its peers' median-6.6%-6.6% against Medical Devices's median of -8.2% (86 companies).
    • ✗Return on equity above 15%-80.1%-80.1% in fiscal 2026.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✗Operating margin wider than three years earlier-6.6%-6.6% in fiscal 2026 against 0.5% in 2023.
  • Financial health1 of 5
    • ✓Short-term assets cover short-term liabilities1.5×Current ratio 1.50 at the end of fiscal 2026.
    • ✗Debt below equity3.5×Debt to equity 3.55 at the end of fiscal 2026.
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • ✗Operating income covers interest five times-0.8×Operating income -0.8 times interest in fiscal 2026.
    • ✗Cash from operations positive in each of the last three years1 of 3Positive in 1 of the three years to fiscal 2026.
    • ✗Altman Z-score outside the distress zone-0.80Z-score -0.80 (distress zone) for fiscal 2026.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Medical Devices, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

What the 2026 statements show#

Each line is an observation with its numbers, not a judgement of the company.

Worth a look

  • Revenue fell 12.3% against the year before.
  • Net loss of $49 million, the 6th loss-making year in a row.
  • Free cash flow was negative: -$13 million.
  • Operating income covers the interest bill only -0.8 times.
  • Goodwill and intangibles ($58 million) exceed shareholders' equity ($42 million).

Piotroski F-score

Nine yes/no tests of whether the company's finances improved in the year. One point each.

1of 9
  • Made a profitno
  • Operations brought in cashno
  • Return on assets roseno
  • Cash from operations exceeds profityes
  • Long-term debt fell against assetsno
  • Current ratio roseno
  • No new shares issuedno
  • Gross margin roseno
  • Asset turnover roseno

Altman Z-score

A 1968 formula that weighs five balance-sheet ratios. It was built on listed manufacturers and says less about other kinds of company.

-0.80Distress zone(below 1.81, where the formula's author found most of the failures)
The five parts of the Altman Z-score
PartRatioWeightPoints
Working capital to assets0.22× 1.20.26
Retained earnings to assets-1.28× 1.4-1.79
Operating income to assets-0.06× 3.3-0.20
Market value to liabilities0.04× 0.60.03
Revenue to assets0.91× 10.91

Profitability#

Accuray Incorporated: profitability by fiscal year
Fiscal yearTrend20262025202420232022Median of peersAhead of
Gross margin27.7%32.1%32.0%34.4%37.2%62.9%7%
Operating margin-6.6%1.7%0.1%0.5%1.9%-8.2%52%
Net margin-12.2%-0.4%-3.5%-2.1%-1.2%-10.4%47%
Return on equity-80.1%-2.5%-31.5%-17.4%-8.8%-16.8%30%
Return on assets-10.8%-0.3%-3.3%-2.0%-1.1%-12.7%52%
Return on invested capital—————10.6%—

Growth#

Accuray Incorporated: growth by fiscal year
Fiscal yearTrend20262025202420232022Median of peersAhead of
Revenue growth-12.3%2.7%-0.2%4.1%8.5%10.4%3%
Revenue growth, 3 years a year-3.5%2.2%4.1%5.3%0.9%10.8%6%
Revenue growth, 5 years a year0.3%3.7%1.3%2.0%2.3%15.3%3%

Financial strength#

Accuray Incorporated: financial strength by fiscal year
Fiscal yearTrend20262025202420232022Median of peersAhead of
Debt to equity3.55×1.68×3.82×3.30×3.39×0.64×10%
Net debt$107 M$79 M$104 M$88 M$92 M$10 M33%
Net debt to EBITDA—5.65×16.19×12.72×6.72×1.68×—
Interest cover-0.80×0.61×0.04×0.22×1.00×-3.82×58%
Current ratio1.50×1.65×1.66×1.70×1.68×3.30×19%
Equity share of assets9.4%17.3%9.6%11.2%11.3%54.6%6%

Cash#

Accuray Incorporated: cash by fiscal year
Fiscal yearTrend20262025202420232022Median of peersAhead of
Free cash flow$-13 M$-1 M$-16 M$3 M$-7 M$-3 M29%
Free cash flow margin-3.2%-0.3%-3.5%0.7%-1.7%-1.9%46%
Cash conversion—————152.3%—
Capital spending share of revenue1.5%0.9%0.8%2.8%1.1%2.5%—

Shareholder returns#

Accuray Incorporated: shareholder returns by fiscal year
Fiscal yearTrend20262025202420232022Median of peersAhead of
Change in share count—4.6%3.6%3.0%0.1%4.1%—

Efficiency#

Accuray Incorporated: efficiency by fiscal year
Fiscal yearTrend20262025202420232022Median of peersAhead of
Asset turnover0.88×0.98×0.94×0.94×0.90×0.64×70%

How each figure is worked out#

Gross margin
Gross profit as a share of revenue.
Operating margin
Operating income as a share of revenue.
Net margin
Net income as a share of revenue.
Return on equity
Net income as a share of shareholders' equity (the average of the start and the end of the year). Not given when equity is negative.
Return on assets
Net income as a share of total assets (average of the year).
Return on invested capital
Operating income after tax, as a share of debt plus equity less cash (average of the year). The tax rate is the year's own: income tax over pre-tax income.
Revenue growth
Revenue against the year before.
Revenue growth, 3 years a year
The yearly rate that takes revenue of three years earlier to this year's.
Revenue growth, 5 years a year
The yearly rate that takes revenue of five years earlier to this year's.
Debt to equity
Total debt divided by shareholders' equity. Not given when equity is negative.
Net debt
Total debt less cash. Negative means more cash than debt.
Net debt to EBITDA
Debt less cash, divided by operating income plus depreciation and amortization: roughly the years of operating earnings needed to repay it.
Interest cover
Operating income divided by the interest paid on debt.
Current ratio
Assets due within a year divided by liabilities due within a year.
Equity share of assets
Shareholders' equity as a share of total assets.
Free cash flow
Cash from operations less capital spending.
Free cash flow margin
Free cash flow as a share of revenue.
Cash conversion
Cash from operations as a share of net income. Only when the year was profitable.
Capital spending share of revenue
Capital spending as a share of revenue.
Change in share count
Diluted shares against the year before. Negative: fewer shares.
Asset turnover
Revenue divided by total assets (average of the year).

Source: Accuray Incorporated's statements: annual reports filed with the SEC. Arithmetic on reported figures, in US dollars; nothing is estimated. A figure is blank when a line it needs is not in the statements on file, and left out when the result cannot be right (a margin from next to no revenue). "Ahead of" is the share of the 102 companies in Medical Devices that Accuray Incorporated is better than on that figure, using each company's newest fiscal year; yields use today's market value. Medians for every industry · Back to Accuray Incorporated